It’s Never
Too Late for Relief Let MIGRANAL® help you gain
control of your migraines.
Do you wait until your migraine is
already at full strength before taking your medication?
Do
you “hoard” your
medication and only use it when the pain becomes unbearable?
With
MIGRANAL® (dihydroergotamine
mesylate), you
no longer have to worry about waiting to take
your medication or of saving your medicine supply
for only the severe attacks.
MIGRANAL can be used at any time during a migraine attack – no
matter what the severity level. In addition, 86% of patients
who’ve taken MIGRANAL are migraine-free up to 24 hours
after treatment. And MIGRANAL is a nasal spray – meaning
it works faster than many oral medications.
Ask your doctor whether MIGRANAL is right for you, and get
powerful relief that works long after your migraine has started.
Print and take this coupon to your next doctor’s visit
to see if MIGRANAL is right for you. Then, with your prescription,
bring it to your pharmacy to receive up to $20 off your co-pay.
IMPORTANT SAFETY INFORMATION:
Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated.
Migranal Nasal Spray should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including Prinzmetal's variant angina. Migranal also should not be given to patients with uncontrolled hypertension, patients who have used 5-HT1 agonists, ergotamine-containing or ergot-type medications or methysergide within the last 24 hours, or patients with hemiplegic or basilar migraine. Migranal Nasal Spray is also contraindicated in patients with known peripheral arterial disease, sepsis, following vascular surgery, and severely impaired hepatic or renal function. Migranal Nasal Spray should not be administered to pregnant women or nursing mothers.
Serious cardiac events, including some that have been fatal, have occurred following use of DHE 45 but are extremely rare. During clinical studies and the foreign postmarketing experience with Migranal Nasal Spray, there have been no fatalities due to cardiac events.
The most commonly reported adverse events in clinical trials for Migranal Nasal Spray were rhinitis, altered sense of taste, application site reactions, dizziness, nausea and vomiting. Adverse events associated with discontinuation were rhinitis, dizziness, facial edema, cold sweats, accidental trauma, depression, elective surgery, somnolence, allergy, vomiting, hypotension, and paresthesia.
